Paraguay Medical Device Registration 2026: Finished Product Quality Control Certificate Requirements
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
- Article 6, item e) requires either a finished product quality control certificate that contains all of the tests needed to ensure the functionality, quality and safety of the product, executed against current standards, or a conformity certificate issued by a notified body (Organismo Notificado).
- Article 12, item e) lists the same requirement in the renewal dossier, which means the evidence must be provided again at every renewal and is not a one-time submission.
- For imported products, the change table in Article 13 adds a further obligation: when the actual manufacturer is replaced, the finished product quality control certificate or the notified body conformity certificate of the new manufacturer must be submitted, together with the updated manufacturer information.
- The distinction from item a) is functional: item a) proves the process, while item e) proves the finished product. The pairing is deliberate: a compliant process does not by itself demonstrate that the product leaving the line conforms, and product testing without a controlled process cannot guarantee the next batch. Item e) therefore never substitutes for item a), and the two are always evaluated together.
2. Legal basis
| Instrument | Number / reference | Date | Provision |
|---|---|---|---|
| Resolution on market authorization requirements for medical devices | Resolución DINAVISA N° 226/2024 | 2024-08-27; Article 36 in force from 2024-09-16 | Article 6, item e); Article 12, item e); Article 13 change table (manufacturer replacement) |
| Operating instructions and guide for submitting applications | Instructivo ITR–DGRS-002, Versión 02 | 2024-09-09 | Article 8 (documents must be valid at the time of issuance) |
Read together, the three provisions of the resolution give item e) a triple role: an entry requirement at initial registration, a recurring requirement at each renewal across the 10-year validity of the certificate, and a change-management requirement whenever the manufacturing site is replaced. The operating instructions add the temporal constraint that the submitted evidence must remain valid at the moment of issuance. Item e) is also the item most exposed to that temporal rule: test evidence ages quickly, and a certificate valid at submission may lapse before the 120-business-day evaluation and its rectification rounds are complete. Tracking item e) against the expected issuance date, alongside items b) and d), keeps the whole dossier inside the validity window at the moment that matters. The dual route of item e) also gives applicants a planning choice: the quality control route draws on in-house testing capacity, while the notified body route draws on an external assessment that already exists.
3. Expert insights
Insight one: the wording all of the tests means that partial reports are not accepted. Item e) demands the complete set of tests that ensure functionality, quality and safety of the finished product. Submitting only one performance report, for instance an electrical safety report alone or a biocompatibility report alone, does not satisfy the item. Manufacturers that already maintain CE technical documentation are usually better served by the notified body route, because the underlying conformity assessment already spans the full test set, and a single notified body certificate can carry the evidentiary weight of dozens of scattered reports. The full set is defined by the product and its intended use, not by convenience, so the test plan should be derived from the risk management file and the applicable standards before any report is commissioned.
Insight two: replacing the manufacturer re-triggers item e). The change table in Article 13 lists the replacement of the actual manufacturer among the situations that require a new quality control certificate or conformity certificate from the incoming manufacturer, accompanied by updated manufacturer information. A supplier switch is therefore not merely a commercial decision; it is a compliance event with its own dossier, its own evaluation and its own lead time. Procurement planning and regulatory planning must be synchronized, so that the change submission is approved before the first batch from the new site reaches the market. The practical consequence is that the incoming manufacturer must be audited and its documentation assembled before the commercial transition, not after, because the change submission and the procurement switch run on different clocks.
Insight three: the recurring renewal requirement makes item e) a standing obligation across the holding period. The registration certificate is valid for 10 years, but quality control evidence is typically issued with a much shorter validity. Keeping item e) on an annual maintenance ledger, with each document tracked from issuance to expiry, prevents the reactive scramble of assembling fresh evidence inside the renewal window, which opens only 120 business days before the certificate expires and leaves no room for slow test laboratories. Where the notified body route is used, the annual ledger should track the notified body certificate itself, since its scope and validity bound what the dossier can claim at any moment.
4. Practical recommendations
- Prepare a finished product quality control certificate covering the full test set, or replace it wholesale with a notified body conformity certificate whose scope matches the product family.
- Keep an annual update ledger for item e), and complete every refresh before the underlying document expires, reconciling the ledger against the laboratory or notified body calendar so that updates are booked before expiry, not after.
- Before switching suppliers, file the change submission first, including the new manufacturer quality control certificate, and switch purchasing only after approval, keeping the outgoing manufacturer valid in the dossier until the approval arrives.
- Compare the renewal dossier against Article 12 item by item, and flag item e) with its own owner and refresh date in the compliance calendar, so the owner sees the deadline alongside the other certificate expiries.
5. Verification checklist
- □ QC certificate or notified body certificate covering the full test set obtained
- □ Certificate scope covers all declared models
- □ Annual update ledger for item e) established
- □ Supplier switch accompanied by a planned change submission
- □ Renewal dossier list includes Article 12, item e)
Regulatory information verified as of October 29, 2026.
GRZAN provides registration and conformity support in Paraguay for medical device manufacturers, importers and authorized representatives, including quality control evidence strategy and change submissions under Article 13. For assistance, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us